Document is current
Any future updates will be listed below
-
Authors
Guerra, Luca https://orcid.org/0000-0003-4197-2060
Albano, Domenico
Angelillo, Piera
Di Rocco, Alice
Farina, Mirko
Farolfi, Andrea
Tarantino, Vittoria
Visco, Carlo
Zinzani, Pier Luigi
-
Funding
Funding for this research was provided by:
Università degli Studi di Milano - Bicocca
- License Information
-
More Information
Article History
Received: 15 May 2026
Accepted: 4 June 2026
First Online: 26 June 2026
Declarations
:
: Not applicable.
: Not applicable.
: Nothing to disclose.
: LG: Gilead Sciences Lecturer; ADR: advisory and consultant for Roche, Takeda, Incyte, Kite-Gilead, Novartis, Abbvie, Eli-Lilly, Recordati-Rare Disease, SOBI, Astazeneca, J&J, BeOne, BMS; CV: advisory and consultant for AbbVie, BMS, Astra Zeneca, Servier, Incyte, Roche, Pfizer, Novartis, Gentili, Johnson & Johnson, Kite-Gilead, BeOne, Lilly, Kyowa Kirin; PLZ: advisory and consultant for ADC Therapeutics, SOBI, Kite-Gilead, Janssen, Bristol Myers Squibb, AstraZeneca, Roche, Kyowa Kirin, Incyte, BeiGene, Merck Sharp & Dohme, Takeda, Recordati, Novartis. All the other Authors declare non conflict of interest.
